Resources

Social Media Guidance from FDA Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on June 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

read more

Tobacco Control Act Substantial Equivalence Rebuttal Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on April 2013 by Michael Levin-Epstein

read more

Adverse Event Reporting and Distinct Naming of Biosimilars Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on March 2013 by Michael Levin-Epstein

read more

Prohibition on Use of Chimpanzees for Biomedical Research Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on March 2013 by Michael Levin-Epstein

read more

Implementing Physician Payment Sunshine Act Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on February 2013 by Michael Levin-Epstein

read more

Consequences of Landmark Second Circuit Decision in United States v. Caronia Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on February 2013 by Michael Levin-Epstein

read more

DEA Guidance on Suspicious Drug Orders Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on January 2013 by Michael Levin-Epstein

read more

Unique Names for All Biologics and Biosimilars Rebuttal Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on January 2013 by Michael Levin-Epstein

read more

Physician Use of Autologous Stem Cell Therapy Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on December 2012 by Michael Levin-Epstein

read more

Pharmacist’s Duty to Warn Patients Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on December 2012 by Michael Levin-Epstein

read more

Resources

Products & Services